BioPharma Dive5h
Approval in hand, Bristol Myers sets out to sell first-of-its-kind schizophrenia drug
While momentous, the approval of Cobenfy could also draw attention to an age-old problem in American healthcare: Will insurance barriers keep patients from getting an effective medicine?
WFSU14h
A new kind of drug for schizophrenia promises fewer side effects
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
New schizophrenia drug ‘could change the lives of millions of people’
New schizophrenia drug ‘could change the lives of millions of people’ - The US Food and Drug Administration has approved ...
Business Wire15h
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of ...
U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...
Bristol-Myers Squibb: Sell Rating Justified by Market Challenges and Drug Uptake Concerns
Terence Flynn, an analyst from Morgan Stanley, maintained the Sell rating on Bristol-Myers Squibb (BMY – Research Report). The associated ...